Announcement on Convening the Q1 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai MicuRx Pharmaceutical
- Announcement on the Resignation of Independent Directors
- Report for Q1 2025
- Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
- MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
- Announcement on Vesting Results in the 1st Vesting Period of Initial Grant in 2023 Restricted Stock Incentive Plan and Shares Listing
Later from Shanghai MicuRx Pharmaceutical
- Announcement on the Voluntary Disclosure of Acceptance of the New Drug Application for the Marketing Authorization of Contezolid Acefosamil Sodium for Injection
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
- Notice on Convening the 1st Extraordinary General Meeting in 2025
- Announcement on Change of Sponsor Representative
Follow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai MicuRx Pharmaceutical